# Carolyn Young

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/carolyn-young/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,393 |
| Field | Amyotrophic Lateral Sclerosis Research |
| h-index | 54 |
| i10-index | 153 |
| Last Known Institution | University of Liverpool |
| OpenAlex ID | https://openalex.org/A5101520669 |
| ORCID iD | 0000-0003-1745-7720 |
| Works | 348 |

## Researcher papers

- [Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis](https://scholariq.org/papers/randomized-controlled-trial-of-cannabis-based-medicine-in-central-pain-in/)
- [Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/effect-of-glatiramer-acetate-on-conversion-to-clinically-definite-multiple/)
- [Achieving Saturation in Thematic Analysis: Development and Refinement of a Codebook](https://scholariq.org/papers/achieving-saturation-in-thematic-analysis-development-and-refinement-of-a/)
- [Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension](https://scholariq.org/papers/effect-of-natalizumab-on-disease-progression-in-secondary-progressive-multiple/)
- [The effect of anti-α4 integrin antibody on brain lesion activity in MS](https://scholariq.org/papers/the-effect-of-anti-4-integrin-antibody-on-brain-lesion-activity-in-ms/)
- [Anti-spasticity agents for multiple sclerosis](https://scholariq.org/papers/anti-spasticity-agents-for-multiple-sclerosis/)
- [Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group](https://scholariq.org/papers/stratification-and-monitoring-of-natalizumab-associated-progressive-multifocal/)
- [Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis](https://scholariq.org/papers/association-of-british-neurologists-revised-2015-guidelines-for-prescribing/)
- [Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial](https://scholariq.org/papers/oromucosal-9-tetrahydrocannabinol-cannabidiol-for-neuropathic-pain-associated/)
- [A medical definition of fatigue in multiple sclerosis](https://scholariq.org/papers/a-medical-definition-of-fatigue-in-multiple-sclerosis/)
- [Health Utilities and Costs for Motor Neurone Disease](https://scholariq.org/papers/health-utilities-and-costs-for-motor-neurone-disease/)

## Researcher topics

- [Amyotrophic Lateral Sclerosis Research](https://scholariq.org/topics/amyotrophic-lateral-sclerosis-research/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Neurogenetic and Muscular Disorders Research](https://scholariq.org/topics/neurogenetic-and-muscular-disorders-research/)
- [Peripheral Neuropathies and Disorders](https://scholariq.org/topics/peripheral-neuropathies-and-disorders/)
- [Parkinson's Disease Mechanisms and Treatments](https://scholariq.org/topics/parkinson-s-disease-mechanisms-and-treatments/)

## Researcher university

- [University of Liverpool](https://scholariq.org/institutions/university-of-liverpool/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.